Mark your calendars now. The Indian generic drug manufacturer Ranbaxy has struck a deal with Pfizer to begin marketing a generic version of the blockbuster anti-cholesterol drug/statin Lipitor at the end of November 2011 according to the Financial Times. Ranbaxy will have 180 days of exclusive marketing rights to generic Lipitor.
Daiichi Sankyo of Japan is seeking to acquire Ranbaxy. The Indian business press reports today that the Bombay stock market which lists Ranbaxy reacted unfavorably to the deal. Reuters reports that the deal caused UBS to cut ratings on two large U.S. prescription benefits managers Medco and Express Scripts as a result of this deal because the UBS analysts expected Lipitor to go generic in 2010.